News | August 17, 2025
Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
NewCo’s pipeline includes five investigational medicines
Subscribe To Our Newsletter & Stay Updated
